Companies to reveal list price reductions to German authorities
This article was originally published in Scrip
Pharmaceutical companies that fail to negotiate a price with German health insurers will likely have to disclose discounts or rebates in the 15 countries to be referenced by the arbitration board that will set German prices. The arbitration board says that companies must report the "actual price" in these countries.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.